Cover Image
市場調查報告書

多發性骨髓瘤:歐洲主要5個國家的醫藥品市場預測與分析

Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 368837
出版日期 內容資訊 英文 175 Pages
訂單完成後即時交付
價格
Back to Top
多發性骨髓瘤:歐洲主要5個國家的醫藥品市場預測與分析 Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023
出版日期: 2015年11月01日 內容資訊: 英文 175 Pages
簡介

歐洲主要5個國家(5EU)的多發性骨髓瘤治療藥的市場有 擴大趨勢。市場成長的主要原因,是高價格品牌藥 (Kyprolis,Empliciti,Daratumumab等)的上市,及Revlimid和Velcade的一般化比美國遲等。

本報告提供歐洲主要5個國家 (法國、德國、義大利、西班牙、英國) 的多發性骨髓瘤的治療藥臨床實驗趨勢與上市預測相關分析,多發性骨髓瘤概要和症狀、原因,目前的主要的治療方法,現在臨床實驗中的開發中產品的概要 (功效,SWOT分析等),市場規模預測 (總計11年份),主要的推動市場要素與其影響度等相關的調查評估。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 近日出版的相關報告

第3章 疾病概要

  • 病因與病情
  • 病期分類
  • 反應、復發的標準
  • 症狀
  • 預後
  • 生活品質 (QoL)

第4章 疾病管理

  • 治療方法概要
  • 診斷
  • 臨床診療
    • 對適合SCT (同類造血幹細胞移植) 的患者的一次治療
    • 對不適合SCT的患者的一次治療
    • 搶救治療/復發時的療法
    • 代表性處方藥
  • 法國
    • 診斷
    • 臨床診療
  • 德國
  • 義大利
  • 西班牙
  • 英國

第5章 競爭產品的評估

  • 概要
  • 產品簡介:蛋白酶體抑制劑
    • Velcade (Bortezomib)
    • Kyprolis (Carfilzomib)
  • 產品簡介:免疫調節藥物
    • Revlimid (Lenalidomide)
    • Pomalyst/Imnovid (Pomalidomide)
  • 其他治療層級

第6章 未滿足需求與市場機會

  • 概要
  • 高風險患者的治療
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 冒煙型骨髓瘤的患者的治療
  • 骨髓外疾病的治療

第7章 開發中產品的評估

  • 概要
  • 臨床實驗階段有潛力的醫藥品
    • Farydak (Panobinostat)
    • ikisazomibu
    • Empliciti (Elotuzumab)
    • Daratumumab
    • Aplidin (Plitidepsin)
  • 臨床實驗的初期階段有潛力的醫藥品
    • Oprozomib (ONX-0912)
    • Filanesib
    • SAR650984
    • marizomibu
    • Evofosfamide
    • LGH447
    • Selinexor (KPT-330)

第8章 市場未來展望

  • (5EU)歐洲主要5個國家
    • 預測
    • 近幾年主要的事件
    • 推動市場要素
    • 阻礙市場要素

第9章 附錄

圖表一覽

目錄
Product Code: GDHC307CFR

The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and daratumumab, which will not only provide a new treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Furthermore, the relatively mild safety profile of these mAbs and the significant efficacies demonstrated by these agents will mean that more MM patients will ultimately receive drug treatment. Label extensions of these mAbs, as well as of second-generation proteasome inhibitors ixazomib and Kyprolis, will further increase treatment options for these patients. The biggest constrainers of the MM market are the increasing cost-consciousness of healthcare providers, as the launch and subsequent label extensions of these pipeline agents will lead to a significant expense, which may impact uptake of these drugs. The patent expiries of Revlimid and Velcade will somewhat alleviate healthcare spending on multiple myeloma patients, which may assist in the uptake of mAbs and second-generation PIs in the multiple myeloma market.

The 5EU market is forecast to show a larger increase in size. This is due to the launch of premium priced Kyprolis, Empliciti, and daratumumab, as well as the later launch of Revlimid and Velcade generics, compared to the US.

Scope

  • Overview of Multiple Myeloma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2014-2024.
  • Analysis of the impact of key events as well the drivers and restraints affecting 5EU Multiple Myeloma market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Multiple Myeloma.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2014-2024 in 5EU.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Staging Systems
  • 3.3. Response and Relapse Criteria
  • 3.4. Symptoms
  • 3.5. Prognosis
  • 3.6. Quality of Life

4. Disease Management

  • 4.1. Treatment Overview
  • 4.2. Diagnosis
  • 4.3. Clinical Practice
    • 4.3.1. Primary Therapy for SCT-Eligible Patients
    • 4.3.2. Primary Therapy for Non-SCT Patients
    • 4.3.3. Salvage/Relapse Therapy
    • 4.3.4. Leading Prescribed Drugs
  • 4.4. France
    • 4.4.1. Diagnosis
    • 4.4.2. Clinical Practice
  • 4.5. Germany
    • 4.5.1. Diagnosis
    • 4.5.2. Clinical Practice
  • 4.6. Italy
    • 4.6.1. Diagnosis
    • 4.6.2. Clinical Practice
  • 4.7. Spain
    • 4.7.1. Diagnosis
    • 4.7.2. Clinical Practice
  • 4.8. UK
    • 4.8.1. Diagnosis
    • 4.8.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles. Proteasome Inhibitors
    • 5.2.1. Velcade (Bortezomib)
    • 5.2.2. Kyprolis (Carfilzomib)
  • 5.3. Product Profiles. Immunomodulators
    • 5.3.1. Revlimid (Lenalidomide)
    • 5.3.2. Pomalyst/Imnovid (Pomalidomide)
  • 5.4. Other Therapeutic Classes

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Treatment of High-Risk Patients
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Treatment of Patients with Smoldering Myeloma
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Treatment of Extramedullary Disease
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Farydak (Panobinostat)
    • 7.2.2. Ixazomib
    • 7.2.3. Empliciti (Elotuzumab)
    • 7.2.4. Daratumumab
    • 7.2.5. Aplidin (Plitidepsin)
  • 7.3. Promising Drugs in Early-Stage Development
    • 7.3.1. Oprozomib (ONX-0912)
    • 7.3.2. Filanesib
    • 7.3.3. SAR650984
    • 7.3.4. Marizomib
    • 7.3.5. Evofosfamide
    • 7.3.6. LGH447
    • 7.3.7. Selinexor (KPT-330)

8. Market Outlook

  • 8.1. 5EU
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers. 5EU
    • 8.1.4. Barriers. 5EU

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Multiple Myeloma Patients
    • 9.4.2. Percent of Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Pricing of Pipeline Agents
    • 9.4.8. Generic Erosion
  • 9.5. Primary Research. KOLs Interviewed for this Report
  • 9.6. Primary Research. High-Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Director
    • 9.7.3. Epidemiologist
    • 9.7.4. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Definition of the Classes of Myeloma
  • Table 2: Staging Systems for Multiple Myeloma
  • Table 3: IMWG Uniform Response Criteria for Multiple Myeloma: Response
  • Table 4: IMWG Uniform Response Criteria for Multiple Myeloma: Progression
  • Table 5: Symptoms of Multiple Myeloma
  • Table 6: Median Survival for Each Stage at Diagnosis of Multiple Myeloma
  • Table 7: Potential Diagnostic Markers that Predict Two-Year Disease Progression
  • Table 8: Summary of Prevalence and Clinical Outcomes of Translocations in Multiple Myeloma
  • Table 9: Treatment Guidelines for Multiple Myeloma
  • Table 10: Definition of the Classes of Myeloma
  • Table 11: Most Prescribed Drugs for Multiple Myeloma by Class in the Global Markets, 2014
  • Table 12: Most-Prescribed Drugs for Multiple Myeloma by Segment in the Global Markets, 2013
  • Table 13: Country Profile - France
  • Table 14: Country Profile - Germany
  • Table 15: Country Profile - Italy
  • Table 31: Country Profile - Spain
  • Table 17: Country Profile - UK
  • Table 18: Product Profile - Velcade
  • Table 19: Results from the Pivotal Phase III APEX Trial for Velcade
  • Table 20: Results from the Pivotal Phase III VISTA Trial for Velcade
  • Table 21 Results from the Subcutaneous versus Intravenous Velcade Phase III trial
  • Table 22: Common Grade 3 and 4 Adverse Events from Velcade Pivotal Clinical Trials
  • Table 23: Velcade SWOT Analysis, 2015
  • Table 24: Global Sales Forecast ($m) for Velcade, 2013-2023
  • Table 25: Product Profile - Kyprolis
  • Table 26 Summary of Phase III Pivotal Trial Results for Kyprolis
  • Table 27: Summary of Phase II Clinical Trial Efficacy Data for Kyprolis
  • Table 28 Summary of Adverse Events from Key Phase III Pivotal Trials for Kyprolis
  • Table 29: Kyprolis SWOT Analysis, 2015
  • Table 30: Global Sales Forecasts ($m) for Kyprolis, 2013-2023
  • Table 31: Product Profile - Revlimid
  • Table 32 Summary of Phase III Pivotal Trial Results for Revlimid in NDMM Patients
  • Table 33 Summary of Phase III Pivotal Trial Results for Revlimid in RRMM Patients
  • Table 34: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Revlimid
  • Table 35: Revlimid SWOT Analysis, 2015
  • Table 36: Global Sales Forecast ($m) for Revlimid, 2013-2023
  • Table 37: Product Profile - Pomalyst
  • Table 38: Summary of PFS, OS, and ORR from Phase II Trial Data for Pomalyst
  • Table 39: Summary of Phase III Trial Data for Pomalyst
  • Table 40: Pomalyst SWOT Analysis, 2015
  • Table 41: Global Sales Forecasts ($m) for Pomalyst, 2013-2023
  • Table 42: Summary of Other Therapeutic Classes, 2015
  • Table 43: Pipeline Product Profile - Farydak
  • Table 44: Summary of the Phase III PANORAMA 1 Trial of Farydak
  • Table 45: Summary of the Phase III PANORAMA 1 Trial of Farydak in Patients Who Recived at Least Two Prior Lines of Therapy (Including Velcade and an IMiD)
  • Table 46: Summary of the Phase II PANORAMA 2 Trial of Farydak
  • Table 47: Grade 3-4 Adverse Events in the Phase III PANORAMA 1 Trial of Farydak
  • Table 48: Farydak SWOT Analysis, 2015
  • Table 49: Global Sales Forecast ($m) for Farydak, 2013-2023
  • Table 50: Pipeline Product Profile - Ixazomib
  • Table 51: Response Results from the Phase II Study of Ixazomib
  • Table 52: Ixazomib SWOT Analysis, 2015
  • Table 53: Global Sales Forecast ($m) for Ixazomib, 2013-2023
  • Table 54: Pipeline Product Profile - Empliciti
  • Table 55: Summary of the Phase III ELOQUENT 2 trial of Empliciti
  • Table 56: Efficacy Results from the Phase II Study of Empliciti with Velcade and Dexamethasone
  • Table 57: Empliciti SWOT Analysis, 2015
  • Table 58: Global Sales Forecast ($m) for Empliciti, 2013-2023
  • Table 59: Pipeline Product Profile - Daratumumab
  • Table 60: Response Results from the Phase II Study of Daratumumab
  • Table 61: Daratumumab SWOT Analysis, 2015
  • Table 62: Global Sales Forecast ($m) for Ddaratumumab, 2013-2023
  • Table 63: Pipeline Product Profile - Aplidin
  • Table 64: Summary of Phase II Clinical Trial Results for Aplidin
  • Table 65: Summary of Grade 3 and 4 Adverse Events of Aplidin
  • Table 66: Aplidin SWOT Analysis, 2015
  • Table 67: Global Sales Forecast ($m) for Aplidin, 2013-2023
  • Table 68: Summary of Efficacy Data from the Phase Ib/II Clinical Trial of Oprozomib
  • Table 69: Summary of the Phase I Efficacy Results of SAR650984
  • Table 70: Summary of the Phase I Efficacy Results of Evofosfamide
  • Table 71: 5EU Sales Forecast, Multiple Myeloma, 2013-2023 ($m)
  • Table 72: Key Events Impacting Sales for Multiple Myeloma in the 5EU, 2013-2023
  • Table 73: 5EU Multiple Myeloma - Drivers and Barriers, 2013-2023
  • Table 74: 5EU Multiple Myeloma - Barriers, 2013-2023
  • Table 75: Multiple Myeloma Diagnosed Incidence, 2013-2023
  • Table 76: Multiple Myeloma Drugs and Pipeline agents, Launch Dates
  • Table 77: Multiple Myeloma Drugs and Pipeline agents, Anticipated Patent Expiries
  • Table 78: Average Cost of Therapy for Velcade
  • Table 79: Average Duration of Treatment (Weeks) for Velcade
  • Table 80: Average Cost of Therapy for Kyprolis ($)
  • Table 81: Average Duration of Treatment (Weeks) for Kyprolis
  • Table 82: Average Cost of Therapy for Revlimid ($)
  • Table 83: Average Duration of Treatment (Weeks) for Revlimid
  • Table 84: Average Cost of Therapy for Pomalyst/Imnovid ($)
  • Table 85 Average Duration of Treatment (Weeks) for Pomalyst/Imnovid
  • Table 86: Average Cost of Therapy for Farydak ($)
  • Table 87: Duration of Treatment (Weeks) for Farydak
  • Table 88: Average Cost of Therapy for Ixazomib ($)
  • Table 89: Duration of Treatment (Weeks) for Ixazomib
  • Table 90: Average Cost of Therapy for Empliciti ($)
  • Table 91: Duration of Treatment (Weeks) for Empliciti
  • Table 92: Average Cost of Therapy for Daratumumab ($)
  • Table 93: Duration of Treatment (Weeks) for Daratumumab
  • Table 94: Average Cost of Therapy for Daratumumab ($)
  • Table 95: Duration of Treatment (Weeks) for Daratumumab
  • Table 96: Numbers of Prescribers Surveyed in Each Country

List of Figures

  • Figure 1: SCT-Eligible Typical Patient Journey
  • Figure 2: Non-SCT-Eligible Typical Patient Journey
  • Figure 3: Velcade's Phase III Development in Multiple Myeloma
  • Figure 4: Kyprolis's Phase III Development in Multiple Myeloma
  • Figure 5: Revlimid's Phase III Development in Multiple Myeloma
  • Figure 6: Pomalyst/Imnovid's Phase III Development in Multiple Myeloma
  • Figure 7: Farydak's Development in Multiple Myeloma
  • Figure 8: Dosing Schedule for Farydak
  • Figure 9: Ixazomib's Development in Multiple Myeloma
  • Figure 10: Empliciti's Development in Multiple Myeloma
  • Figure 11: Daratumumab's Development in Multiple Myeloma
  • Figure 12: Annual 5EU Sales for Multiple Myeloma by Region, 2013-2023
  • Figure 13: Annual 5EU Sales for Multiple Myeloma by Drug, 2013-2023
  • Figure 14: 5EU Sales for Multiple Myeloma by Drug, 2013 and 2023
Back to Top